menu
    • menu
    [{"orgOrder":0,"company":"Exelead","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Exelead","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Exelead \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Exelead \/ Pfizer"},{"orgOrder":0,"company":"Exelead","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exelead","amount2":0.78000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.78000000000000003,"dosageForm":"","sponsorNew":"Exelead \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Exelead \/ Merck"}]

    Find Clinical Drug Pipeline Developments & Deals by Exelead

    Menu

    Exelead

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Exelead

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Exelead

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Merck Group

                            Deal Size : $780.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Definitive Agreement to Acquire Exelead will Strengthen Merck’s CDMO Offering for mRNA

                            Details : Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology which is key in mRNA-based vaccines for use in Covid-19 and many other indications.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : $780.0 million

                            January 06, 2022

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Merck Group

                            Deal Size : $780.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Exelead

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Exelead

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tozinameran

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Exelead Inks deal to Manufacture Lipid Nanoparticles for Pfizer/bio N Tech Vaccine

                            Details : Exelead, has delivered its first vaccine precursor batch manufactured at its facility, as part of an agreement with Pfizer for the Pfizer-BioNTech COVID-19 Vaccine, BNT162b2.

                            Brand Name : BNT162b2

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 10, 2021

                            Lead Product(s) : Tozinameran

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth